Treatment options in androgen-independent prostate cancer

Research output: Contribution to journalArticle

28 Citations (Scopus)

Abstract

Metastatic prostate cancer is a leading cause of cancer-related death in men. Although most patients will respond to androgen ablation as initial systemic therapy, nearly all patients will develop androgen-independent prostate cancer (AI CaP) and will succumb to the disease. Advances in molecular biology have demonstrated mutations in and persistent expression of the human androgen receptor in metastatic disease. Furthermore, recent evidence indicates that an apoptotic block through p53 mutations or bcl-2 overexpression may have a potential role in the poor responses seen with standard chemotherapy. Presently, the six general treatment options available for AI CaP are best supportive care, radiation therapy, radioisotopes, secondline hormonal therapy, chemotherapy (single agent or combination), and investigational therapies such as monoclonal antibodies, cyclin-dependent kinase inhibitors, matrix metalloproteinase inhibitors, and antiangiogenesis agents, among others. None of these modalities have produced durable remissions, although some have demonstrated palliative benefit. The next generation of clinical trials should not consist of futile hormonal manipulations or repetitive chemotherapy. Therapeutic strategies aimed at circumventing molecular blocks to cell death or targeting unique cancer molecules and genes will be more likely to improve quality of life and longevity. Furthermore, the aggressive use of palliative care will ensure effective caring for patients and the healing of families in the absence of cure.

Original languageEnglish (US)
Pages (from-to)137-144
Number of pages8
JournalCancer Investigation
Volume17
Issue number2
StatePublished - 1999

Fingerprint

Androgens
Prostatic Neoplasms
Drug Therapy
Mutation
Investigational Therapies
Matrix Metalloproteinase Inhibitors
Cyclin-Dependent Kinases
Neoplasm Genes
Therapeutics
Palliative Care
Radioisotopes
Molecular Biology
Cell Death
Radiotherapy
Monoclonal Antibodies
Quality of Life
Clinical Trials
Neoplasms

Keywords

  • Androgen-independent
  • Chemotherapy
  • Hormone refractory
  • Prostate cancer
  • Treatment

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Treatment options in androgen-independent prostate cancer. / Lara, Primo N; Meyers, Frederick J.

In: Cancer Investigation, Vol. 17, No. 2, 1999, p. 137-144.

Research output: Contribution to journalArticle

@article{643c5fe87c464e3e8b0486d18fa4918e,
title = "Treatment options in androgen-independent prostate cancer",
abstract = "Metastatic prostate cancer is a leading cause of cancer-related death in men. Although most patients will respond to androgen ablation as initial systemic therapy, nearly all patients will develop androgen-independent prostate cancer (AI CaP) and will succumb to the disease. Advances in molecular biology have demonstrated mutations in and persistent expression of the human androgen receptor in metastatic disease. Furthermore, recent evidence indicates that an apoptotic block through p53 mutations or bcl-2 overexpression may have a potential role in the poor responses seen with standard chemotherapy. Presently, the six general treatment options available for AI CaP are best supportive care, radiation therapy, radioisotopes, secondline hormonal therapy, chemotherapy (single agent or combination), and investigational therapies such as monoclonal antibodies, cyclin-dependent kinase inhibitors, matrix metalloproteinase inhibitors, and antiangiogenesis agents, among others. None of these modalities have produced durable remissions, although some have demonstrated palliative benefit. The next generation of clinical trials should not consist of futile hormonal manipulations or repetitive chemotherapy. Therapeutic strategies aimed at circumventing molecular blocks to cell death or targeting unique cancer molecules and genes will be more likely to improve quality of life and longevity. Furthermore, the aggressive use of palliative care will ensure effective caring for patients and the healing of families in the absence of cure.",
keywords = "Androgen-independent, Chemotherapy, Hormone refractory, Prostate cancer, Treatment",
author = "Lara, {Primo N} and Meyers, {Frederick J}",
year = "1999",
language = "English (US)",
volume = "17",
pages = "137--144",
journal = "Cancer Investigation",
issn = "0735-7907",
publisher = "Informa Healthcare",
number = "2",

}

TY - JOUR

T1 - Treatment options in androgen-independent prostate cancer

AU - Lara, Primo N

AU - Meyers, Frederick J

PY - 1999

Y1 - 1999

N2 - Metastatic prostate cancer is a leading cause of cancer-related death in men. Although most patients will respond to androgen ablation as initial systemic therapy, nearly all patients will develop androgen-independent prostate cancer (AI CaP) and will succumb to the disease. Advances in molecular biology have demonstrated mutations in and persistent expression of the human androgen receptor in metastatic disease. Furthermore, recent evidence indicates that an apoptotic block through p53 mutations or bcl-2 overexpression may have a potential role in the poor responses seen with standard chemotherapy. Presently, the six general treatment options available for AI CaP are best supportive care, radiation therapy, radioisotopes, secondline hormonal therapy, chemotherapy (single agent or combination), and investigational therapies such as monoclonal antibodies, cyclin-dependent kinase inhibitors, matrix metalloproteinase inhibitors, and antiangiogenesis agents, among others. None of these modalities have produced durable remissions, although some have demonstrated palliative benefit. The next generation of clinical trials should not consist of futile hormonal manipulations or repetitive chemotherapy. Therapeutic strategies aimed at circumventing molecular blocks to cell death or targeting unique cancer molecules and genes will be more likely to improve quality of life and longevity. Furthermore, the aggressive use of palliative care will ensure effective caring for patients and the healing of families in the absence of cure.

AB - Metastatic prostate cancer is a leading cause of cancer-related death in men. Although most patients will respond to androgen ablation as initial systemic therapy, nearly all patients will develop androgen-independent prostate cancer (AI CaP) and will succumb to the disease. Advances in molecular biology have demonstrated mutations in and persistent expression of the human androgen receptor in metastatic disease. Furthermore, recent evidence indicates that an apoptotic block through p53 mutations or bcl-2 overexpression may have a potential role in the poor responses seen with standard chemotherapy. Presently, the six general treatment options available for AI CaP are best supportive care, radiation therapy, radioisotopes, secondline hormonal therapy, chemotherapy (single agent or combination), and investigational therapies such as monoclonal antibodies, cyclin-dependent kinase inhibitors, matrix metalloproteinase inhibitors, and antiangiogenesis agents, among others. None of these modalities have produced durable remissions, although some have demonstrated palliative benefit. The next generation of clinical trials should not consist of futile hormonal manipulations or repetitive chemotherapy. Therapeutic strategies aimed at circumventing molecular blocks to cell death or targeting unique cancer molecules and genes will be more likely to improve quality of life and longevity. Furthermore, the aggressive use of palliative care will ensure effective caring for patients and the healing of families in the absence of cure.

KW - Androgen-independent

KW - Chemotherapy

KW - Hormone refractory

KW - Prostate cancer

KW - Treatment

UR - http://www.scopus.com/inward/record.url?scp=0344572787&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0344572787&partnerID=8YFLogxK

M3 - Article

C2 - 10071598

AN - SCOPUS:0344572787

VL - 17

SP - 137

EP - 144

JO - Cancer Investigation

JF - Cancer Investigation

SN - 0735-7907

IS - 2

ER -